Industrial Postdoc - Molecular Biology, mNGS Project
About the job
- A PhD in molecular biology, genetics, genomics, biochemistry, or microbiology is required.
- At least one first-author publication stemming from doctoral work is required.
- At least four years of experience in wet-lab experimentation and a deep understanding of different molecular biology tools are required.
- Familiarity with bioinformatics and data analysis tools is required.
- Ability to meticulously design, plan, and execute complex experimental designs, analyze large data sets, and interpret results using statistics when applicable is required.
- Ability to articulate concise reports that convey key findings is required.
- Exceptional written and verbal communication skills are required.
- Originate new ideas in metagenomics next-generation sequencing (mNGS), sample preparation, and host depletion for diverse clinical specimen types.
- Maintain cultures of microorganisms, including bacteria and viruses.
- Design and execute experiments, analyze results, and report conclusions.
- Assume ownership of key projects and perform prerequisite tasks independently.
- Optimize assay conditions with statistical decision-making to achieve commercial levels of stability, robustness, and performance.
- Contribute as an individual contributor and collaborative team member.
- Communicate with colleagues and supervisors through oral updates, written reports, and technical meetings.
- Maintain a detailed record of all research avenues pursued.
- Experience developing mNGS workflows and/or host depletion solutions is a plus.
- Experience in grant writing, grant management, and project management is a plus.
About the company
Clear Labs delivers diagnostic solutions for healthcare and food safety using whole genome sequencing (WGS) and next-generation sequencing (NGS) to detect infectious disease outbreaks and to test food for safety. Its flagship Clear Dx Microbial Surveillance WGS provides an automated end-to-end sequencing system for bacterial and fungal isolates. It also offers SARS-CoV-2 surveillance and wastewater monitoring to expand its surveillance services and markets. Its goal is to enable faster, more accurate detection and monitoring of infectious diseases and foodborne pathogens to protect public health and support business growth.
Company Size
51-200
Company Stage
Series D
Total Funding
$150.2M
Headquarters
San Carlos, California
Founded
2014
Get referred to Clear Labs
See people who can refer or advise you
Simplify's Take
What believers are saying
- March 2026 Labcorp partnership targets streamlined oncology NGS workflows.
- July 2026 rebranding clarifies Clear Ix infectious-disease products and reduces customer confusion.
- The 2025 $30 million Series D still funds commercialization and assay expansion.
What critics are saying
- Revelio Labs counted 83 employees in March 2026, down 12.6% since 2023.
- Only two 2026 job postings signal a thin sales and regulatory execution bench.
- A failed oncology pivot traps the company below scale and starves future financing.
What makes Clear Labs unique
- Clear Labs automates sample-to-answer NGS workflows, cutting manual steps across diagnostics.
- Its 2026 Clear Dx oncology platform extends automation beyond infectious disease RUO.
- Labcorp collaboration and Clear Ix rebrand show one platform spanning research and clinical workflows.
Help us improve and share your feedback! Did you find this helpful?
Benefits
- Flexible Work Hours
- Meal Benefits
- Health Insurance
- Dental Insurance
- Vision Insurance
- Life Insurance
- Disability Insurance
- Employee Assistance Program
- Stock Options